Format

Send to

Choose Destination
Cancer Cell. 2016 Sep 12;30(3):432-443. doi: 10.1016/j.ccell.2016.08.002. Epub 2016 Sep 1.

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Author information

1
Department of Internal Medicine (Cardiology), Yale Cardiovascular Research Center, Yale University, New Haven, CT 06520, USA. Electronic address: mansoornccs@gmail.com.
2
Department of Surgery, University of Colorado, Aurora, CO 80045, USA.
3
Mathematics and Computer Science Department, Eastern Connecticut State University, Willimantic, CT 06226, USA.
4
Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA.
5
Department of Surgery, University of Colorado, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado, Aurora, CO 80045, USA; University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA. Electronic address: dan.theodorescu@ucdenver.edu.
6
Department of Internal Medicine (Cardiology), Yale Cardiovascular Research Center, Yale University, New Haven, CT 06520, USA; Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT 06520, USA. Electronic address: martin.schwartz@yale.edu.

Abstract

RhoGDI2 specifically suppresses bladder cancer metastasis but not primary tumor growth, which involves tumor-associated macrophages. We report that macrophage-secreted osteopontin binds to CD44s on the tumor cells and promotes invasion and clonal growth. These effects are RhoGDI2-sensitive and require CD44s binding to the Rac GEF TIAM1. Osteopontin expression correlates with tumor aggressiveness and poor clinical outcome in patients. Inhibiting this pathway potently blocked lung and lymph node metastasis; however, primary tumors and established metastasis were less sensitive. Osteopontin-CD44s-TIAM1 promotes clonal growth in vitro but not at high cell density. These data identify osteopontin-CD44-TIAM1-Rac1 axis as a RhoGDI2-sensitive pathway and potential therapeutic target in bladder cancer metastasis. They also elucidate the mechanism behind RhoGDI2 specificity for metastasis over established tumors.

PMID:
27593345
PMCID:
PMC5154333
DOI:
10.1016/j.ccell.2016.08.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center